

REMARKS


After amendment herein, claims 1-6, 8, 10-21, 23, and 25 will be pending. Claims 1-5, 10-21, and 25 have been withdrawn as being directed to a non-elected invention. Claims 7, 9, 22, 24, and 26 have been canceled. No new matter has been added by these amendments.

Claim Objections

Claim 9 remains objected to under 37 CF 1.75(c) as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicants have canceled claim 9 herein and therefore request that the objection be withdrawn.

Rejections Under 35 U.S.C. § 102

Claims 6, 8, 9 and 23 were rejected under 35 U.S.C. § 102 as being anticipated by Firschling et al. (Cancer Research (1995), 55 (November 1), 4957-4961). Firschling et al. was cited as disclosing the compound




Applicants respectfully submit that the Office action is mistaken in finding that NF130 falls within the scope of the claim 6. Claim 6 discloses a polyamido moiety comprising one unit of formula II (-CO-A-B-NH-) bound to one or more other units selected from units of formula II or moieties of formula III (-CO-E-NH-). NF130 contains a moiety of the formula -CO-A-B-NH-CO-NH-B-A-CO-. The two units of NF130 are bound together by a -CO- group; they are not bound together. Thus, compound NF130 of Firschling et al. does not fall within the scope of claim 6. As a result, claim 6 is not anticipated by Firschling et al. Claims 8 and 23 are patentable for at least the reasons discussed herein with respect to claim 6.

Applicants respectfully request reconsideration and withdrawal of the rejection in view of the arguments set forth herein.

CONCLUSION

In light of the amendments and remarks presented herein, Applicants submit that the claims are patentable and respectfully request allowance of the claims.

Respectfully submitted,


Charlene L. Yager
Reg. No. 48,887

Michael Best & Friedrich LLP
One South Pinckney Street
P. O. Box 1806
Madison, WI 53701-1806
608.257.3501